Intraperitoneal Therapy for Advanced Ovarian Cancer

Inclusion Criteria: * Patients aged 18 to 75 years, * Patients with high-grade serous (high grade according to MD Anderson, grade II and III according to Silverman) ovarian or tubal or primitive peritoneal histologically proven cancer, * Initial laparoscopy confirming the histological type, evaluating the extent of the disease by PCI score and confirming the initial non-resectability, * Stage III B-C (FIGO 2014) or stage IVA with minimal or moderate pleural effusion (measured on a thoracic CT scanner, the largest thickness of which is less than 3 cm), * Complete interval cytoreduction surgery, * Indication of 3 to 4 cures of neoadjuvant chemotherapy based on the Carboplatin-Paclitaxel (carbo-taxol) combination, * The delay between the last course of NAT and the surgery must be between 4 and 8 weeks, * Hematologic function, hemoglobin ≥ 10 g / dl; PNN ≥ 1 x 109 / L, platelets ≥ 100 x 109 / L, * Total bilirubin ≤ 1.5 LSN, ALT or AST ≤ 3 ULN, * Absence of renal insufficiency (creatinine clearance ≤ 70 ml / min) according to the MDRD method, * Informed consent signed before any specific procedure under consideration, * Patients affiliated to the French social security scheme or equivalent. Exclusion Criteria: * Performance Index (WHO) ≥ 2, * Stage IV B or IV A with significant pleural effusion (measured on a thoracic CT scanner, the largest thickness of which is more than 3 cm), * Renal impairment (clearance \<70 ml / min) according to the MDRD method, * General contraindication to the realization of a tumor reduction surgery or HIPEC (contraindication or history allergic reaction to any treatments components), * Hepatic insufficiency (bilirubin \> 1.5 x normal, ASAT \& ALAT \> 3 x upper limit of normal), * Serious life-threatening co-existing condition at stake, * Cardio-respiratory pathology indicating hyper hydration, to be implemented for HIPEC, * Patient who has already been treated with chemo-hyperthermia for ovarian cancer, * History of cancer, except basal cell carcinoma of the skin or carcinoma in situ of cervix having recurred within five years prior to entry into this trial, * Any severe untreated infectious disease, * Peripheral sensory neuropathy ≥ grade 2 at the inclusion time, * Patients whose regular follow-up is a priori impossible for psychological, family, social or geographical reasons, * Pregnant and / or nursing women, * Subjects under tutelage, curatorship or safeguard of justice.